Aetna sees FY13 EPS at least $5.40, consensus $5.53 Sees FY13 revenue growing approximately 9% over FY12 levels, consensus $38.69B. In 2013, projects that full-year Commercial medical cost trend will remain at 6.5% ± 0.5%, as increased benefit buy-downs relative to 2012 levels and the absence of leap year impacts reduce year-over-year comparisons. Guidance expected to be given during J.P Morgan Healthcare Conference on January 8 and 9.
News For AET From The Last 14 Days
Check below for free stories on AET the last two weeks.
Aetna price target raised to $72 from $67 at Susquehanna Susquehanna raised its price target on Aetna following the closing of its acquisition of Coventry Health as management anticipates earnings accretion to double over the next couple of years. Near-term the firm believes the company is well positioned to exceed its 2013 guidance. Shares are Positive rated.